Quantcast
Home > Quotes > ZSAN

Zosano Pharma Corporation Common Stock (ZSAN) Quote & Summary Data

ZSAN 
$3.4
*  
0.09
2.58%
Get ZSAN Alerts
*Delayed - data as of Apr. 18, 2019  -  Find a broker to begin trading ZSAN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
19
Today's High / Low
$ 3.53 / $ 3.36
Share Volume
770,434
50 Day Avg. Daily Volume
2,880,667
Previous Close
$ 3.49
52 Week High / Low
$ 6.65 / $ 1.85
Market Cap
40,708,333
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.5

Intraday Chart

Shares Traded

Share Volume:
770,434
50 Day Avg. Daily Volume:
2,880,667

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -6.44

Trading Range

The current last sale of $3.40 is 83.78% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.53 $ 6.65
 Low: $ 3.36 $ 1.85

Company Description (as filed with the SEC)

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM, technology. In February 2017, we announced positive results from our ZOTRIP pivotal efficacy trial, or ZOTRIP trial, that evaluated Qtrypta(TM) (M207), which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. In February 2019, we announced the completion of the final milestone in our long-term safety study for Qtrypta(TM) (M207). We are focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, in markets where patients remain underserved by existing therapies.  ... More ...  



Risk Grade

Where does ZSAN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.48
Open Date:
Apr. 18, 2019
Close Price:
$ 3.40
Close Date:
Apr. 18, 2019


Consensus Recommendation

Analyst Info